› Forums › General Melanoma Community › Methodist Estabrook Cancer Center in Omaha has the very promising PLX4032 study that will not randomize anyone to DTIC
- This topic has 2 replies, 1 voice, and was last updated 14 years ago by SusanE.
- Post
-
- September 22, 2010 at 5:03 pm
Please refer to the above link for the New York Times article that talks about this very promising drug called PLX 4032 – a highly selective V600E BRAF kinase inhibitor that is found to be effective in melanoma. Unlike the study discussed in the NYT article, the study that we have will not randomize patients to DTIC (old chemotherapy regimen). As long as the patient's melanoma is BRAF positive, they are given PLX 4032. For more details, please contact Elisa Bomgaars, MD at 402-354-5860. We are recruiting patients still but the study will complete accrual soon.
Viewing 1 reply thread
- Replies
Viewing 1 reply thread
- You must be logged in to reply to this topic.